Researchers are investigating pirtobrutinib in patients with CLL, SLL, and MCL.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Researchers sought to determine whether post-transplantation consolidation with pembrolizumab would be an option for patients with PTCL.
Loncastuximab tesirine produced durable responses in a phase 2 trial of patients with relapsed or refractory DLBCL.
Researchers sought to determine whether liso-cel would lead to responses in patients with relapsed/refractory FL.
Researchers sought to determine whether liso-cel would be effective in patients with relapsed/refractory LBCL.
Researchers sought to determine whether adding metformin to R-CHOP would be safe and effective in patients with DLBCL.
Researchers sought to determine whether mosunetuzumab monotherapy would improve outcomes in patients with relapsed/refractory FL.
Researchers sought to determine the work ability for survivors of Hodgkin lymphoma after diagnosis.
Patients who have more mitochondrial DNA fraction breaks have a higher risk of developing non-Hodgkin lymphoma, according to new research.
Researchers sought to determine the optimal AUC dose for fludarabine and the impact it would have on PFS in patients with aggressive NHL.
Researchers sought to determine whether expansion of NK cells with IL-15 and nicotinamide would improve responses in patients with NHL and MM.
Denileukin diftitox is an engineered IL-2-diphtheria toxin fusion protein.
Researchers sought to determine whether combination pembrolizumab and vorinostat would improve responses in patients with relapsed or refractory B-cell lymphomas.
Researchers sought to determine whether pembrolizumab would induce long-term responses in heavily pretreated patients with relapsed or refractory PMBCL.
Zanubrutinib is as effective as — but safer than — ibrutinib for patients with Waldenström macroglobulinemia, a phase 3 trial suggests.
Researchers sought to determine whether pirtobrutinib would be effective in patients with CLL/SLL who progress after receiving treatment with a BTK inhibitor.
Young patients with lymphoma or rhabdomyosarcoma may experience changes in body composition during chemotherapy, research suggests.
Researchers sought to determine characteristics of late relapse in patients with DLBCL.
Researchers sought to determine the impact of mental health disorders on overall survival and lymphoma-specific survival in patients with DLBCL.
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
Researchers sought to determine whether ibrutinib would improve survival in patients with relapsed/refractory FL or MZL.
Researchers sought to determine whether BrECADD would be as effective as eBEACOPP in patients with advanced-stage classical Hodgkin lymphoma.
Researchers sought to determine whether it would be possible to omit radiotherapy in some patients with PMBCL.
Researchers sought to determine whether AFM13 monotherapy would yield clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
Researchers sought to determine whether orelabrutinib would be effective in patients with relapsed/refractory MZL.
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
Researchers sought to determine whether adding brentuximab vedotin to nivolumab, doxorubicin, and dacarbazine would be a helpful first-line treatment for cHL.
Researchers sought to determine whether capivasertib would be an effective treatment for patients with relapsed/refractory follicular lymphoma.
HDC-ASCT improves outcomes vs immunochemotherapy in newly diagnosed primary CNS lymphoma, a phase 3 study suggests.
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
Researchers sought to evaluate the management of relapsed/refractory lymphoma in pregnant patients.
Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed with a novel 2:1 structural format.
A majority of lymphoma patients who relapse during pregnancy can have a live birth, even if treatment is initiated antenatally, a study suggests.
Researchers sought to determine the prevalence and outcomes of molecular subgroups in patients with DLBCL.
Researchers sought to analyze the immune microenvironment in Waldenström macroglobulinemia to determine any actionable targets.
Researchers sought to determine whether CAR-T therapy with axi-cel would be effective long-term in patients with refractory LBCL.
Researchers sought to determine whether golidocitinib would have antitumor response in patients with relapsed or refractory PTCL.
Researchers sought to determine whether combination atezolizumab, obinutuzumab, and venetoclax would lead to responses in patients with the DLBCL variant of Richter syndrome.
Researchers sought to determine whether radiotherapy could be avoided in patients with PMBCL following chemotherapy.
Researchers sought to determine whether axi-cel would have efficacy and safety for treating follicular lymphoma in a real-world setting compared with the ZUMA-5 trial.
Researchers sought to determine whether axi-cel would improve overall survival rates in patients with LBCL.
Researchers sought to determine whether epcoritamab would be effective in patients with LBCL.
Researchers sought to determine whether copanlisib would have a response in patients with relapsed/refractory indolent follicular lymphoma.
Researchers sought to determine whether zilovertamab vedotin would have antitumor activity in patients with relapsed/refractory DLBCL.
Researchers sought to determine risk of developing SPMs among patients with DLBCL based on race/ethnicity.
Researchers sought to determine whether nivolumab would improve PFS compared with brentuximab vedotin in patients with advanced-stage cHL.
Researchers conducted rRNA and WGS sequencing to determine any link between gut microbial dysbiosis and R-CHOP treatment outcomes among patients with DLBCL.
Load More